AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01920087
Drug: ATNC05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
Trial: NCT01920087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
Trial: NCT00663364
Drug: Physiogel AI Lotion, Physiogel Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
Trial: NCT01426009
Drug: Placebo EP-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo EP-101 administered once daily for 7 days
Trial: NCT01426009
Drug: EP-101 via nebulizer (eFlow®) 200 ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 (200) ug administered once daily for 7 days
Trial: NCT01610297
Drug: ICL670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of ICL670 at 10 mg/kg daily
Trial: NCT05293808
Drug: aspirin 100 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Trial: NCT02449915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
Trial: NCT00451074
Drug: Gentamicin infusions twice a week for six months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin infusions twice a week
Trial: NCT00681902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet saline
Trial: NCT04063540
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment by Amiloride vs placebo in crossover
Trial: NCT00117026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for benfotiamine
Trial: NCT00273624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04063540
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by Amiloride vs placebo in crossover
Trial: NCT00016341
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02393612
Drug: Anplag tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anplag tab 100mg is administrated to patients with PAD for 12 weeks
Trial: NCT00941707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
Trial: NCT04145193
Drug: Standard of Care - mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
Trial: NCT02121002
Drug: Voltaren Topical Gel, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opaque, white gel
Trial: NCT02121002
Drug: Vehicle Diclofenac Sodium Topical Gel
RxNorm normalized name: diclofenac sodium Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opaque, white gel
Trial: NCT01891084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
Trial: NCT01891084
Drug: Backup NSAID ibuprofen
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
Trial: NCT00811395
Drug: Interferon-β [IFN-β]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Trial: NCT00052585
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00052585
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02728180
Drug: Xingnaojing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
Trial: NCT04572724
Drug: RAS Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
Trial: NCT01985334
Drug: ICS
RxNorm normalized name: ICSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
Trial: NCT00914589
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
Trial: NCT01290341
Drug: NAFT-600 (naftin 2 % gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical; applied once daily for two weeks
Trial: NCT01290341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical; applied once daily for two weeks.
Trial: NCT02422706
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KLacid twice daily
Trial: NCT02422706
Drug: Doxicycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vibramycin 100 mg twice daily
Trial: NCT00960141
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet, taken orally once daily at bed time for 2 weeks
Trial: NCT00182975
Drug: DHEA replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04291092
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy for brain metastasis
Trial: NCT04291092
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for brain metastasis
Trial: NCT01095796
Drug: Atripla Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Atripla tablet administered orally once daily prior to bedtime
Trial: NCT03082690
Drug: DuoGel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% IQP-0528 in gel formulation
Trial: NCT03349723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single rising dose groups
Trial: NCT00779116
Drug: Zyrtec® (cetirizine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
Trial: NCT03818893
Drug: Combination of GEN0101 and Pembrolizmub
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Combination immunotherapy GEN0101 and Pembrolizmub
Trial: NCT04192916
Drug: DOACs
RxNorm normalized name: Doans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants
Trial: NCT04050540
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
Trial: NCT01128855
Drug: 3 mg/kg GSK2402968
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injection
Trial: NCT01128855
Drug: 6 mg/kg GSK2402968
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injection
Trial: NCT01128855
Drug: 12 mg/kg GSK2402968
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injection
Trial: NCT01602224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01989455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: normal saline solution.
Trial: NCT03966898
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT00263094
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00999167
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: 6 mL BID for 16 weeks.
Trial: NCT00999167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: same as experimental arm
Trial: NCT01428479
Drug: GR121167 Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
Trial: NCT01428479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered intravenously.
Trial: NCT02516306
Drug: EV06 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01417546
Drug: NHS-IL-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
Trial: NCT02217839
Drug: DG3173
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217839
Drug: DG3173 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04452318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC or IM injections
Trial: NCT01196091
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Trial: NCT03928522
Drug: hand mixed tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hand mixed tobramycin into cement
Trial: NCT01196091
Drug: Placebo every 2 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
Trial: NCT01196091
Drug: Placebo every 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection for 52 weeks.
Trial: NCT01196091
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01649895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills as adjunct to internet-based cognitive-behaviour therapy
Trial: NCT04214106
Drug: intravenous Thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who received Thiamine,100-500 mg/day for at least one day
Trial: NCT02620501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% Normal Saline
Trial: NCT02918617
Drug: Control toothpaste containing Novamin® technology
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Control toothpaste containing 1500 ppm fluoride as MFP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Test toothpaste with nano-HAP (high concentration)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Test toothpaste with nano-HAP (low concentration)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Control toothpaste without nano-HAP
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Test toothpaste with nano-HAP (medium concentration)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Test cream with nano-HAP (higher concentration)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918617
Drug: Control cream without nano-HAP
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03577275
Drug: NST-4016 600mg
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Likely maximum therapeutic dose of NST-4016
Trial: NCT03577275
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for comparison with moxifloxacin and potential NST-4016 effects
Trial: NCT03577275
Drug: NST-4016 2000mg
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic dose of NST-4016
Trial: NCT00002682
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002682
Drug: Tetracycline Hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00259545
Drug: Retarded Release Phosphatidylcholine (rPC)
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03346434
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, subcutaneous (SC)
Trial: NCT04075955
Drug: Zyprexa® (OLANZapine 5MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)
Trial: NCT04075955
Drug: Emend® (Aprepitant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)
Trial: NCT01714336
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
Trial: NCT02202161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Trial: NCT02828618
Drug: 3 cycles of standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 more cycles (for a total of 6) of standard chemotherapy after IDS
Trial: NCT01830829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00474136
Drug: Intravenous diclofenac sodium (DIC075V) 18.75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIC075V 18.75 mg
Trial: NCT00474136
Drug: Intravenous diclofenac sodium (DIC075V) 37.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIC075V 37.5 mg
Trial: NCT00474136
Drug: Oral diclofenac potassium 50 mg
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac potassium 50 mg
Trial: NCT00665340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00383552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo metered dose inhaler twice a day for 26 weeks
Trial: NCT02172872
Drug: standard combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days
Trial: NCT00191438
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01688479
Drug: Essex® cream (Schering-Plough), aqueous cream without parabens
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00280917
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02169466
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC, Opicapone
Trial: NCT02169466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLC, Placebo
Trial: NCT02169466
Drug: Madopar® HBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: controlled-release levodopa 100 mg/benserazide 25 mg
Trial: NCT00171327
Drug: valsartan, fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03323385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once Daily
Trial: NCT03831607
Drug: KHK7791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
Trial: NCT00033293
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02490904
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
Trial: NCT02490904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blinded Placebo administered for 4 days at 25mg every 12 hours
Trial: NCT01339676
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically appearing once weekly peroral placebo capsules
Trial: NCT02802735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT00854568
Drug: CEOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Trial: NCT00854568
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Trial: NCT00957034
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch
Trial: NCT00957034
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 or 450 micrograms/day transdermal testosterone patch
Trial: NCT00533910
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same as the experimental arm
Trial: NCT01086813
Drug: AZD3043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose/IV, bolus over 60secs - infusion over 30 mins
Trial: NCT02818335
Drug: LY3023414 Test Fasted
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT00021281
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00021281
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00021281
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02324413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00529113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules x 28 days
Trial: NCT02675946
Drug: CGX1321
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00609336
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00631969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet